These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 16806598

  • 1. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K.
    Vaccine; 2006 Sep 11; 24(37-39):6240-9. PubMed ID: 16806598
    [Abstract] [Full Text] [Related]

  • 2. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice.
    Ohama M, Hiramatsu K, Miyajima Y, Kishi K, Nasu M, Kadota J.
    FEMS Immunol Med Microbiol; 2006 Jun 11; 47(1):107-15. PubMed ID: 16706793
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU, Domdey H, Schödel F, Blum B, Lücking C, Knapp B, Muth G, Hungerer KD, Bröker M.
    Behring Inst Mitt; 1994 Dec 11; (95):85-96. PubMed ID: 7538752
    [Abstract] [Full Text] [Related]

  • 5. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
    Neely AN, Holder IA, Wiener-Kronish JP, Sawa T.
    Burns; 2005 Mar 11; 31(2):153-8. PubMed ID: 15683685
    [Abstract] [Full Text] [Related]

  • 6. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET, Ervin SE, Wozniak DJ, Mizel SB.
    Vaccine; 2009 Nov 12; 27(48):6762-9. PubMed ID: 19744586
    [Abstract] [Full Text] [Related]

  • 7. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
    Johansen HK, Cryz SJ, Hougen HP, Moser C, Høiby N.
    Behring Inst Mitt; 1997 Feb 12; (98):269-73. PubMed ID: 9382750
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
    Lu YC, Li MC, Chen YM, Chu CY, Lin SF, Yang WJ.
    Vaccine; 2011 Oct 13; 29(44):7740-6. PubMed ID: 21835218
    [Abstract] [Full Text] [Related]

  • 10. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB, Glasier LM, Ellert NW, Cachia P, Kohn W, Lee KK, Paranchych W, Hodges RS, Irvin RT.
    Biomed Pept Proteins Nucleic Acids; 1995 Oct 13; 1(3):141-8. PubMed ID: 9346845
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T.
    Hum Vaccin Immunother; 2016 Nov 13; 12(11):2833-2846. PubMed ID: 27454613
    [Abstract] [Full Text] [Related]

  • 13. Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.
    Li P, Wang X, Sun X, Guan Z, Sun W.
    mSphere; 2021 Oct 27; 6(5):e0069921. PubMed ID: 34612675
    [Abstract] [Full Text] [Related]

  • 14. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S, Naito Y, Katoh H, Shimizu M, Kinoshita M, Akiyama K, Kainuma A, Moriyama K, Ishii KJ, Sawa T.
    Microbiol Immunol; 2017 Feb 27; 61(2):64-74. PubMed ID: 28370521
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, Kohno S.
    Eur Respir J; 2007 May 27; 29(5):965-8. PubMed ID: 17301098
    [Abstract] [Full Text] [Related]

  • 18. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
    Gartner T, Baeten M, Otieno S, Revets H, De Baetselier P, Huygen K.
    Immunol Lett; 2007 Jul 31; 111(1):26-35. PubMed ID: 17570535
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
    Price BM, Barten Legutki J, Galloway DR, von Specht BU, Gilleland LB, Gilleland HE, Staczek J.
    FEMS Immunol Med Microbiol; 2002 Jun 03; 33(2):89-99. PubMed ID: 12052563
    [Abstract] [Full Text] [Related]

  • 20. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice.
    Liu S, Gong Q, Wang C, Liu H, Wang Y, Guo S, Wang W, Liu J, Shao M, Chi L, Zhao K, Wang Z, Shi Y, Huang Y, Guli A, Zhang C, Kong X.
    Immunol Lett; 2008 May 15; 117(2):136-45. PubMed ID: 18339431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.